SCHEMBL4406797

SCHEMBL4406797

CC(C)(C)OC(=O)NC(=O)OC(C)(C)C.Cc1cccc(C2CCN(C(=O)O)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 1/20 0.47
▸ KMT2A Q03164 2/20 0.44
▸ TP53 P04637 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ DRD4 P21917 3/20 0.43
▸ DRD2 P14416 2/20 0.43
▸ DRD3 P35462 1/20 0.43
▸ LIPE Q05469 1/20 0.43
▸ ADAM10 O14672 1/20 0.43
▸ MMP2 P08253 1/20 0.43
▸ MMP9 P14780 1/20 0.43
▸ USP5 P45974 1/20 0.42
▸ ADAM17 P78536 1/20 0.42
▸ ADAMTS5 Q9UNA0 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ NAMPT P43490 1/20 0.41
▸ HDAC4 P56524 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30563607 0.83 GPR119 (0.65) GPR119KMT2ATP53MAPTMEN1
SCHEMBL4398499 0.83 EPHX2 (0.46) GPR119KMT2AMAPTNPC1DRD4
SCHEMBL4395917 0.82 HTR2C (0.63) GPR119HDAC4HTR2C
SCHEMBL4395895 0.80 BCL2 (0.41) GPR119KMT2ATP53MAPTDRD4
SCHEMBL29880399 0.79 GPR119 (0.59) GPR119KMT2ATP53MAPTNPC1
SCHEMBL12320994 0.79 GPR119 (0.59) GPR119KMT2ATP53MAPTNPC1
SCHEMBL4403355 0.77 LMNA (0.41) KMT2ANPC1RAB9ADRD2MEN1
SCHEMBL12479648 0.76 USP30 (0.44) GPR119NPC1SMN1; SMN2NAMPT
SCHEMBL12479659 0.76 PDE4B (0.51) NAMPT
SCHEMBL19711151 0.75 QDPR (0.61) KMT2ATP53MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296972-B1 ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS AVENTIS PHARMA INC (US) 2009-12-23 — — EP disclosed
US-6977263-B2 Chemical compounds AVENTIS PHARMACEUTICALS INC. (US) 2005-12-20 — — US disclosed
US-20050228018-A1 Chemical compounds AVENTIS PHARMACEUTICALS INC. (US) 2005-10-13 — — US disclosed
US-20030187020-A1 Chemical compounds AVENTISUB LLC 2003-10-02 — — US disclosed
EP-1296972-A1 ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS Aventis Pharmaceuticals Inc. (US) 2003-04-02 — — EP disclosed
WO-2001090101-A1 ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2001-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228018-A1 Chemical compounds CMA1, TPSB2, TPSG1 GPR119 723/4885KMT2A 2305/4885TP53 4261/4885
US-20030187020-A1 Chemical compounds CMA1, TPSB2, TPSG1 GPR119 723/4885KMT2A 2305/4885TP53 4261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback